FDA approval for Convenia RTU puts Zoetis in focus
Zoetis (ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose injectable antibiotic for bacterial skin infections, expanding its established Convenia franchise in companion animal medicine.
The FDA green light lands at a tricky moment for Zoetis. The shares trade at US$81.03 after a 30 day share price return of 14.05%. However, the year to date share price return is down 35.65% and the 5 year total shareholder return has declined 59.92%. This signals recent momentum picking up after a much weaker long run and suggests investors may be reassessing both growth prospects and risk around the business.
Scan for other animal health and veterinary stocks showing fresh momentum and resilient fundamentals with our curated 28 high quality undervalued stocks alongside Zoetis after this FDA approval.
Zoetis now trades at US$81.03, with analyst targets and intrinsic value estimates pointing to a wide gap. After this sharp rebound, what is a reasonable fair value range for the stock today?
Most Popular Narrative: 12.8% Undervalued
Against the last close at $81.03, the most widely followed narrative on Zoetis pegs fair value around $92.92, implying a material valuation gap that investors are now weighing against slow but positive earnings trends and the fresh FDA approval for Convenia RTU.
World's leading animal pharma company at 13x PE with 9% EPS growth. Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock. There are hints of genuine value in the position, but I figured there wouldn’t be enough people interested in their single-digit growth. I already finished the analysis halfway, so I thought I’d share it with those who are interested in it.
Find out how 29 investors see Zoetis as 13% undervalued.
According to ValueInvestingSubstack, Zoetis combines a long record of positive earnings progression, including 6.9% annual profit growth over the last five years, with steady revenue expansion and a focused position in companion animals and livestock. That narrative frames the current pricing as a discount to a resilient franchise that reports $9.5b in annual revenue and $2.6b in net income while paying a 2.62% dividend yield.
The same analysis flags key tension points for readers to weigh, especially the use of debt funded buybacks, a high overall leverage position and a sharp recent drop in U.S. companion animal revenue that contributed to the share price reset. Earnings are forecast to grow around 2.9% per year and revenue around 2% per year, which is slower than the broader U.S. market, so the valuation story here leans more on quality and cash flow strength than on rapid expansion.
Putting those threads together, the Simply Wall St narrative model applies a 7.108% discount rate and arrives at a fair value estimate of $92.92 per share, around 12.8% above the last close. That sits between the intrinsic value range of $190.68 implied by the SWS DCF work and the $93 analyst price target, and it reflects an assessment that Zoetis offers high return on equity and strong profitability, offset by leverage and modest growth expectations.
Result: Fair Value of $92.92 (UNDERVALUED)
Still, the Zoetis story could be knocked off course if the U.S. companion animal weakness deepens or if debt funded buybacks start to worry lenders.
Find out about the key risks to this Zoetis narrative.
Next Steps
Curious whether Zoetis looks more like a cautious opportunity or a value trap at this stage of the reset in expectations? Act quickly, review both the caution flags and upside drivers, and ground your view in the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Zoetis?
Do not stop your research with Zoetis. Broaden your watchlist with a few targeted filters that surface specific kinds of opportunities other investors may be overlooking.
- Target stability first and hunt for resilient businesses with lower risk profiles by scanning the 30 resilient stocks with low risk scores to help smooth out portfolio swings.
- Prioritise balance sheet strength and focus on companies with cleaner finances using the list of solid balance sheet and fundamentals (24 results) so you are not caught off guard by hidden leverage.
- Zoom in on potential future leaders before they hit the mainstream by working through the 21 high quality undiscovered gems while others stay parked in the usual blue chips.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com